COVID-19: Vaccine-induced immune thrombotic thrombocytopenia.
FI Danish, AE Rabani, FE Subhani… - European Journal of …, 2022 - europepmc.org
In late February 2021, a prothrombotic syndrome was encountered for the first time in some
of the recipients of ChAdOx1 CoV-19 vaccine (AstraZeneca, University of Oxford, and Serum …
of the recipients of ChAdOx1 CoV-19 vaccine (AstraZeneca, University of Oxford, and Serum …
Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26. COV2. S vaccination
PA Kulkarni, V Prasad - Frontiers of Medicine, 2021 - Springer
On April 13, 2021, the US Centers for Disease Control and Prevention (CDC) and the US
Food and Drug Administration (FDA) recommended a pause in administration of the Ad26 …
Food and Drug Administration (FDA) recommended a pause in administration of the Ad26 …
Vaccine‐induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) is a rare but severe
immunological reaction to the non‐replicable adenoviral vector‐based COVID‐19 vaccines …
immunological reaction to the non‐replicable adenoviral vector‐based COVID‐19 vaccines …
Refractory vaccine‐induced immune thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE)
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) is a newly described
hematologic disorder, which presents as acute thrombocytopenia and thrombosis after …
hematologic disorder, which presents as acute thrombocytopenia and thrombosis after …
The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia
AL Bissola, M Daka, DM Arnold, JW Smith… - Blood …, 2022 - ashpublications.org
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but serious adverse
syndrome occurring 5 to 30 days after adenoviral vector COVID-19 vaccination. Therefore, a …
syndrome occurring 5 to 30 days after adenoviral vector COVID-19 vaccination. Therefore, a …
[HTML][HTML] A case of idiopathic thrombocytopenic purpura after booster dose of BNT162b2 (Pfizer-Biontech) COVID-19 vaccine
Vaccination is now considered the best measure in minimizing the morbidity and mortality
from the Covid-19 pandemic. Almost all the vaccines are considered safe except for minor …
from the Covid-19 pandemic. Almost all the vaccines are considered safe except for minor …
[HTML][HTML] Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis
Objectives To meta-analyse the clinical manifestations, diagnosis, treatment, and mortality of
vaccine-induced immune thrombotic thrombocytopenia (VITT) after adenoviral vector …
vaccine-induced immune thrombotic thrombocytopenia (VITT) after adenoviral vector …
Longitudinal Characteristics of Anti-Platelet Factor 4 Immunoglobulin G in Vaccine-Induced Immune Thrombotic Thrombocytopenia
Introduction: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare
complication of adenoviral vector-based vaccines against the SARS-CoV-2 virus. VITT …
complication of adenoviral vector-based vaccines against the SARS-CoV-2 virus. VITT …
Vaccine‐induced immune thrombocytopenia and thrombosis (VITT)
The coronavirus disease 2019 (COVID-19) pandemic has affected every part of the world,
causing major morbidity and mortality as well as impacting heavily on the economy of every …
causing major morbidity and mortality as well as impacting heavily on the economy of every …
SARS-CoV-2 vaccine–induced immune thrombotic thrombocytopenia
DB Cines, JB Bussel - New England Journal of Medicine, 2021 - Mass Medical Soc
The coronavirus disease 2019 (Covid-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) stimulated the development of highly effective …
syndrome coronavirus 2 (SARS-CoV-2) stimulated the development of highly effective …